Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
J Clin Pharm Ther
; 34(5): 607-10, 2009 Oct.
Article
em En
| MEDLINE
| ID: mdl-19744017
ABSTRACT
Chronic myelogenous leukemia (CML) is one of the myeloproliferative disorders. It accounts for 15-20% of all leukemias in adults. The mainstay of diagnosis is the detection of Philadelphia chromosome or one of its products. Tyrosine kinase inhibitors changed the paradigm of treating such disease with the good responses. However, they do have side effects. In our case we will report tumor lysis syndrome happening after starting Imatinib myselate. We did a literature review and looked all the cases that documented this complication.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piperazinas
/
Pirimidinas
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Síndrome de Lise Tumoral
/
Inibidores de Proteínas Quinases
/
Antineoplásicos
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
J Clin Pharm Ther
Assunto da revista:
FARMACIA
/
TERAPEUTICA
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
Estados Unidos